Pediatric Neurologist & Clinical Scholar, University of Minnesota
- Pediatric Neurologist & Clinical Scholar
- Neurology - Pediatric, Pediatrics - Neurology
- Minneapolis, Minnesota
Pediatric Neurology & Clinical Scholar Opportunity
University of Minnesota Masonic Children’s Hospital
The University Of Minnesota Department Of Neurology is seeking a Child Neurologist with interest in Pediatric Neurophysiology to contribute to the clinical and scholarly momentum within the Division of Child Neurology. The opportunity is most advantageous to the Child Neurologist with career aspirations requiring a balanced focus on subspecialty clinical program building and related clinical or translational research initiatives.
The incoming Child Neurologist will benefit from a balanced emphasis on the expansion of the pediatric epilepsy clinical program and associated research initiatives. Noteworthy attributes of the opportunity include
- Original Level 4 Comprehensive Epilepsy Center
- Anti-seizure medication centered Orphan Drug Research and Development Program
- Large multi-site adult and pediatric epilepsy outpatient program
- Fully staffed pediatric epilepsy surgery program
- Protected time to focus on research initiatives
- No RVU or clinical volume pressure
- Support to write first author peer review articles and grants
- Collegial, inter-disciplinary organizational model
- Access to resources and expertise via NIH funded centers of excellence
Qualified candidates must be board eligible/certified Child Neurologists with fellowship training and expertise in either Epilepsy or Clinical Neurophysiology/EEG and are qualified for a medical license in the state of Minnesota. Candidates should demonstrate a clinical proclivity toward medically managed cases with an interest in concurrently assisting the department meet its longer term objective to develop a pediatric epilepsy surgery program. The incoming Child Neurologist will be appointed as qualified, on the Clinical Scholar Track at the academic rank of Assistant Professor, Associate Professor or Professor in the Department of Neurology with a secondary appointments as applicable.
Candidates with visa needs (J1 or H1B) are encouraged to apply.
Adult and Pediatric Epilepsy Program Overview
Founded at the University of Minnesota in 1964, MINCEP was one of three original comprehensive epilepsy centers in the United States and has served as a model for epilepsy centers around the world. In 2013, MINCEP was integrated within the University Of Minnesota Department of Neurology with the intent of improving patient experience and outcome through a coordinated care model and advanced capabilities, specifically within pharmacology, diagnostics and surgery.
Today, the University of Minnesota Epilepsy program is supported by epilepsy trained neurologists, neurosurgeons, neuropsychologists, neuro-pharmacologists, neuro-radiologists, psychiatrists, epilepsy nurses, speech therapists and social workers. Over 3,500 adult and pediatric cases are treated per year at multiple locations throughout the greater Minneapolis area.
Level 4 Comprehensive Epilepsy Center
The University of Minnesota Epilepsy program meets the standards of the National Association of Epilepsy Centers for a Level 4 Epilepsy Center. Intractable adult and pediatric cases requiring continuous monitoring and diagnosis are admitted to the 8 bed Epilepsy Monitoring Unit (EMU) located at the University of Minnesota Medical Center. The EMU also has access to 6 portable units for bedside use external to the EMU, including those located at the University of Minnesota Masonic Children’s Hospital.
Pediatric Epilepsy Surgery
Pediatric cases deemed to be potential candidates for surgery are presently referred externally for diagnosis and surgical treatment. The incoming Child Neurologist will actively participate in the planning and implementation of a pediatric epilepsy surgery program to be located at the University of Minnesota Masonic Children’s Hospital. While not required, the ideal candidate will possess the ability to support Grid placement and mapping.
Child Neurology Outpatient Clinic Specifics
The University of Minnesota Division of Pediatric Neurology clinical programs are based at the University of Minnesota Masonic Children’s Hospital which is conveniently accessible to the Department of Neurology offices by either indoor or outdoor means. The number of outpatient clinics that faculty are assigned per week is a function of the remaining time available after considering the amount of time protected for research and allocated for administrative follow-up.
All faculty enjoy protected time for research, the degree to which is determined largely based on the attainment of grants. All faculty regardless of grant status enjoy a minimum of 20% protected time for research. Protected time is not encroached upon by inpatient or outpatient clinical duties or administrative follow-up. Faculty that do not have a direct leadership role or defined administrative responsibility are generally provided with one half day per week for administrative follow-up time. The clinical load for all incoming faculty ramps up methodically over a period of approximately 6 months in order to allow for adjustment to University processes and procedures.
Child Neurology Inpatient Service & Call Specifics
The incoming Child Neurologist should expect to work as an attending neurologist on the inpatient service at the University of Minnesota Masonic Children’s Hospital for a total not to exceed 3 full months per year, based on 7-10 day blocks of service. The inpatient pediatric neurology census averages 1-2 patients, with general ward consults typically limited to 5-6 patients most frequently admitted into Pediatric Blood and Marrow Transplantation Program.
Residents and fellows are present at night, thus reducing most nightly interaction to infrequent telephone calls. Faculty on call very rarely travel in to the hospital at night.
University of Minnesota Pediatric Neurology faculty do not take trauma call at the nearby Level 1 Trauma Service located at the Hennepin County Medical Center, an academic affiliate of the University of Minnesota. However, stabilized pediatric trauma patients are frequently transferred to the University of Minnesota Masonic Children’s Hospital.
Department of Neurology Overview
The Department of Neurology at the University of Minnesota is led by Dr. Jerrold L. Vitek, MD, PhD, Professor and Chairman of the Department of Neurology, and nationally recognized physician/scientist from the standpoint of both non-human primate and human clinical studies on the neurophysiology of movement disorders and neuromodulation mechanisms.
Since its inception in 1946, the Department has been dedicated to high quality clinical care and internationally recognized research oriented accomplishments, obtained in large measure due to the effective embracement of interdisciplinary/interdepartmental collaboration.
Today, interdisciplinary collaboration crosses all major disciplines including Neurosurgery, Psychiatry, Pediatrics, Psychology, Pharmacy, Radiology/Neuroradiology, ENT, Biomedical Engineering and Neuroscience. A new program in vestibular and balance disorders is being developed and will interdisciplinary oriented.
The Department also collaborates with colleagues in the Center for Magnetic Resonance Research (CMRR), the Institute of Human Genetics, the Division of Epidemiology and Community Health (School of Public Health), and the Brain Sciences Center and Geriatric Research and Education Clinical Center (GRECC) at the Minneapolis VA Medical Centers.
Division of Child Neurology Overview
The University of Minnesota emphasizes a holistic approach to child and adolescent care with focus on family and community contexts. Children with complex neurological and behavioral problems receive coordinated care from pediatricians, neurologists, other medical and surgical specialists, neuropsychologists, and specialty pediatric neurology nurses.
Several University of Minnesota faculty exemplify the benefit realized from the University’s commitment to interdepartmental/interdisciplinary medicine and research, as highlighted below
Dr. Gerald V. Raymond, M.D., Professor of Neurology and Chief of Pediatric Neurology
Dr. Raymond focuses on the study of X-linked Adrenoleukodystrophy (ALD) and other neurogenetic conditions. He works in close collaboration with the Pediatric Blood and Bone Marrow Transplantation Program, the Center for Orphan Drug Research, the Center for Magnetic Resonance Research, and others, to develop new tools to diagnose, manage, and treat all aspects of ALD.
Dr. Michael Georgieff, Professor of Pediatrics, Director of the Division of Neonatology and Director of the Neonatal Center for Neurobehavioral Development
Dr. Georgieff was selected by his peers as the 2014 recipient of the American Academy of Pediatrics (AAP) Samuel J. Fomon Nutrition Award. This award recognizes an individual for outstanding achievement in research relating to the nutrition of infants and children. Dr. Georgieff’s research focuses on the effect of fetal/neonatal iron nutrition on brain development and neurocognitive function.
Dr. James Cloyd, Pharm D. is a Morse Alumni Distinguished Teaching Professor of Pharmacy, the Lawrence C. Weaver Endowed Chair in Orphan Drug Development, and Director of the Center for Orphan Drug Research at the University of Minnesota College Of Pharmacy.
Dr. Cloyd’s research focuses on the clinical pharmacology of CNS drugs, specifically pediatric. He holds 9 INDs and has served as principal or co-principal investigator for a number of Phase I-Phase III trials, many of which have supported NDA applications. He co-authored the orphan drug application for the widely prescribed diazepam rectal gel (Diastat) and was a key leader in the successful development of the antiepileptic product. The National Institutes of Health, the Food and Drug Administration, foundations, and the pharmaceutical industry have funded his research, which has led to 100 papers in major medical and pharmacology journals as well as book chapters on various aspects of CNS drugs.
Dr. Cloyd is actively involved in several international and national organizations including the International Conference on Rare Diseases and Orphan Drugs and the American Epilepsy Society, where he served on the Board of Directors from 2009-11.
Dr. Harry T. Orr, PhD. Professor of Laboratory Medicine and Pathology and Director of the Institute for Translational Neuroscience
Dr. Orr is focused on the molecular genetics of mammalian development and neurodegenerative diseases. He and his colleagues recently cloned the gene for an autosomal dominant form of spinocerebellar ataxia (SCA 1).
Dr. Orr is also Director of the Institute for Translational Neuroscience (expanded in the research overview below), which purposefully brings together researchers that have synergistic strengths in basic movement disorder-oriented neuroscience research, and clinical neurosciences. In addition, these researchers collaborate with several different groups including the NINDS Institutional Center Core grant, the Bob Allison Ataxia Research Center and the Paul and Sheila Wellstone Muscular Dystrophy Center.
Dr. Timothy J. Ebner, M.D., PhD., Professor and Chair of the Department of Neuroscience and the Max E. and Mary LaDue Pickworth Endowed Chair in Neuroscience
Dr. Ebner is the Department Head of Neuroscience, which has over 100 full time faculty and one of the largest neuroscience graduate programs in the country. Dr. Ebner leads research associated with the study of how single neurons and populations of neurons encode the information needed to plan and execute limb movements. The goal is to decipher how the brain represents different movement parameters and then uses this information to control movements. His team is investigating both kinematic and dynamic movement parameters, recording the activity of neurons in the cerebellum and cerebral cortex in primates during motor behaviors.
Dr. Dante Cicchetti, PhD., McKnight Presidential Chair, William Harris Professor of Child Psychology
Dr. Cicchetti leads the US’ #1 ranked graduate Child Psychology Program, according to US News and World Report in 2013. Professor Cicchetti’s major research interests lie in the formulation of an integrative developmental theory that can account for both normal and abnormal forms of ontogenesis. His work has several foci: 1) a multiple levels of analysis developmental psychopathology perspective; 2) the developmental consequences of child maltreatment; 3) neural plasticity and sensitive periods; 4) the impact of traumatic experiences upon brain development; 5) the biology and psychology of unipolar and bipolar mood disorders; 6) the study of attachment relations and representational models of the self and its disorders across the life span; 7) multilevel perspectives on resilience; 8) multilevel evaluations of Randomized Control Trial (RCT) interventions for depressed and maltreated children and adolescents; and 9) epigenetics.
University of Minnesota Research Overview
The University of Minnesota is ranked in the top 20% of US Medical Schools in terms of total NIH funding, thus demonstrating a clear institution wide commitment to research. Highlighted
below are specific research programs at the University of Minnesota which create powerful points of leverage for pediatric neurologists with near and longer term clinical and translational research.
Human Connectome Project (HCP)
The Human Connectome Project, or HCP, has brought the combined brainpower of 36 investigators — including six from the University of Minnesota —from 11 different institutions to bear on the challenges of understanding the human brain.
In 2010, the National Institutes of Health awarded almost $40 million in grants to support brain mapping and imaging research efforts by two consortia. The largest grant — $30 million over five years — was awarded to a consortium led by Washington University in St. Louis and the University of Minnesota.
The WU-Minn. consortium was tasked with optimizing MRI scanners, related technologies, and data acquisition methods to capture the most advanced images ever of the brain’s anatomical wiring (using diffusion-weighted MRI) and its activity (using functional MRI or fMRI), both in resting state and while the subject is performing various tasks.
In total, the WU-Minn Connectome Project will acquire high-resolution MRI brain scans from 1,200 healthy adults. This group will include 300 sets of four siblings — each set consisting of a pair of twins and two non-twin siblings. In addition to brain scans, the project will collect genetic information and behavioral data for each subject. Washington University is conducting the majority of the scans, but the University of Minnesota will conduct even higher-resolution scans — both 7T and 10.5T — of a subset of the larger group. The researchers believe that by comparing these different scans of the same individuals, they will be able to learn more about how various parts of the brain interact.
A second consortium, led by Massachusetts General Hospital/Harvard University and UCLA, received an $8.5 million grant to perform similar studies using diffusion MRI technology for imaging the brain’s structural connections. Both research groups will make their data freely available to neuroscientists and other researchers around the world. The WU-Minn. consortium has begun releasing data from the scans acquired to date.
Center for Magnetic Resonance Research (CMRR)
Established in 1991, the CMRR is an interdepartmental and interdisciplinary research laboratory that provides state-of-the-art instrumentation, expertise, and infrastructure to carry out biomedical research utilizing the unique capabilities provided by high field MRI and MRS methodology.
The central aim of the research conducted in CMRR is to non-invasively obtain functional, physiological, and biochemical information in intact biological systems, and use this capability to probe biological processes in health and disease. Which focuses on the development of unique magnetic resonance (MR) imaging and spectroscopy methodologies and instrumentation for the acquisition of structural, functional, and biochemical information non-invasively in humans, and utilizing this capability to investigate organ function in health and disease.
Funded by the NIH as a Biotechnology Research Resource for High field Magnetic Resonance Imaging and Spectroscopy, and supported by numerous governmental and private foundations, CMRR core faculty have made significant and pioneering contributions in biological applications of magnetic resonance techniques, and possess unique expertise in very high field uses of this methodology. CMRR faculty conducts research in a variety of areas including
- High field functional brain mapping in humans; methodological developments, mechanistic studies, and neuroscience applications
- Metabolism, bioenergetics, and perfusion studies of human pathological states (tumors, obesity, diabetes, hepatic encephalopathy, cystic fibrosis, and psychiatric disorders)
- Cardiac bioenergetics under normal and pathological conditions
- Automated magnetic field shimming methods that are critical for spectroscopy and ultrafast imaging at high magnetic fields
- Development of high field magnetic resonance imaging and spectroscopy techniques for anatomic, physiologic, metabolic, and functional studies in humans and animal models
- Radiofrequency (RF) pulse design based on adiabatic principles
- Development of magnetic resonance hardware for high fields (e.g. RF coils, pre-amplifiers, digital receivers, phased arrays, etc.)
- Development of software for data analysis and display for functional brain mapping.
- Resources include:
- 10.5 Tesla / 89 cm Bore system for human studies (world’s largest)
- 16.4 Tesla for animal model studies
- 9.5 (2) Tesla for animal model studies
- 7 Tesla (shielded MR System for Human Studies; eye tracking)
- Cyclotron – Siemens PETNET
- 17.0 Tesla 5cm Vertical Bore
- 4 Tesla for human studies
- Siemens Inveon preclinical microPET/CT
- 3 Tesla (multiple, w/advanced imaging)
Neuromodulation Research Center and Lab (NRCL)
The NRCL develops multi-scale computational neuron models to further understanding of the biophysical and physiological mechanisms of neuromodulation. In partnership with the Minnesota Supercomputing Institute, the NRCL couples finite element models of electric fields generated in neural tissue with computational neuron models built from sets of mathematical equations that replicate the biophysical properties of membrane and synapse dynamics.
The NRCL also investigates the therapeutic mechanisms of neuromodulation experimentally through multi-channel electrophysiological and neurochemical techniques in animal models of movement disorders. The NRCL is particularly interested to determine how neurons encoding movement are modulated during deep brain stimulation, how stimulation at different therapeutic efficacies influences these neurons, and how the modulation of neuronal firing patterns changes during chronic stimulation.
The NRCL is developing new types of implants and stimulation strategies that are inspired by the underlying neuroscience. The NRCL evaluates these technologies with the goal of leveraging industrial partnerships to translate these therapies from the laboratory to the clinic.
Dr. Jerrold Vitek, M.D. PhD, Professor and Chair of Neurology directs a large interdisciplinary neuromodulation research program at the NRCL which is primarily centered on understanding the pathophysiology of movement disorders such as Parkinson’s disease and dystonia as well as the mechanisms underlying the therapeutic effect of deep brain stimulation.
Center for Orphan Drug Research (CODR)
Since its inception in 2005 within the College of Pharmacy, the CODR has been improving the care of individuals suffering from rare diseases through research, increased education efforts, and by taking an active role in shaping public policy applicable to rare diseases and orphan drug development (conditions with less than 200k affected people). The focus of CODR research is on rare pediatric neurological disorders.
CODR projects are focused on identifying new therapies for
- Seizure Disorders, including:
- Infantile spasms
- Seizure control in neonates
- Canine epilepsy
- Seizure emergencies
- Neurodegenerative disorders, including:
- Late-state Adrenoleukodystrophy
- Gaucher’s and Parkinson’s Diseases
- Baclofen withdrawal
- Improving Orphan Product Development
- Post-Phar.D. Fellowship in Clinical Pharmacotherapy
- Pharmacogenetics of Inherited Metabolic Disease
Center for Neurobehavioral Development (CNBD)
The Center for Neurobehavioral Development is a research center that houses over thirty studies about children’s cognitive and neurobehavioral functioning.
The mission of the CNBD is to understand how brain development affects the way children think, learn and express emotions. CNDB research focuses on typically developing, atypically developing, and at-risk children. The goal is to understand brain and behavioral development throughout childhood, from infancy through adolescence. The work conducted at the CNBD revolves around three thematic cores:
- Investigating the neural underpinnings of cognitive and emotional development in typically developing children.
- Examining the neurobiological effects of early adversity (e.g. perinatal complications, malnutrition, and institutionalization) on the developing brain in at-risk children.
- Undertaking the clinical neuroscience approach to intervention and prevention in children diagnosed with or at risk for developing neuro- and psychopathology.
The CNBD provides the administrative support, educational tools and physical space needed to support researchers from many different fields. University departments involved in the CNBD include Departments of Pediatrics, Neuroscience, Psychology, Psychiatry, Radiology, Educational Psychology, Kinesiology, Speech and Language Hearing Sciences, the Medical School, the School of Nursing, and the Institute of Child Development.
The Institute for Translational Neuroscience (ITN)
The ITN was established in 2007 as a Presidential, University-wide initiative in order to promote the transfer of discoveries in the basic neurosciences to clinical practice. The institute is charged to enhance basic science discovery with new knowledge leading to subsequent clinical trials and establishment of new therapeutic principles or tools. The institute aims to attract and recruit top scientists to shape discoveries that will lead to tomorrow’s cures. The ITN exemplifies how different disciplines, departments and centers can work together in partnership to evolve neurological disease research at the University of Minnesota.
The founding centers of the ITN, include
- Center for Magnetic Resonance Research (CMRR)
- Center for Neuroengineering (CNE)
- Center for Neurodegenerative Disease (CND)
- N. Bud Grossman Center for Memory Research and Care
Center for Neuroengineering (CNE)
The CNE was established in 2007 to enhance neuroengineering research at the University of Minnesota as part of the Institute for Translational Neuroscience. The CNE is now also affiliated with the Institute for Engineering in Medicine. Bridging neuroscience and engineering, neuroengineering is an emerging field that translates research discoveries into neuro-technologies that provide new and powerful tools for basic and clinical neuroscience research and lead to enhanced patient care. For example, developments in brain-machine interface (BMI) technology exemplify the dramatic progress and potential of neuroengineering. Another successful example is Deep Brain Stimulation (DBS), in which functional electrical stimulation has been demonstrated to treat patients with Parkinson’s disease and a host of other nervous system disorders. These two examples demonstrate the feasibility of translating neuroscience findings into technologies that can directly impact patient care.
The University of Minnesota has strong, highly recognized research groups in engineering and neuroscience that provide the underpinning for an initiative in neuroengineering. Coupled with the strong medical device industry in Minnesota such as Medtronic, Boston Scientific, St. Jude Medical and Cyberonics, the University is uniquely positioned to seize this opportunity to enhance neuroengineering research and translate findings into new technologies and products. The CNE is aimed at bringing together and building upon the rich existing strengths at the University of Minnesota to address the unique opportunity in the emerging field of neuroengineering. The CNE has identified thrust areas of interdisciplinary research and training in neural interfacing and modulation, neuroimaging, and neural computation. The CNE will offer an opportunity to foster on-campus collaborations among faculty in the basic sciences, engineering, and clinical departments as well as collaborations with the biomedical industry.
Center for Neurodegenerative Disease (CND)
The overarching goal of the CND is to bring together researchers that have synergistic strengths in basic movement disorder-oriented neuroscience research, and clinical neurosciences. In addition, these researchers collaborate with several different groups including the NINDS Institutional Center Core grant, the Bob Allison Ataxia Research Center and the Paul and Sheila Wellstone Muscular Dystrophy Center.
The Bob Allison Ataxia Research Center (BAARC) at the University of Minnesota is a comprehensive program for basic science research, clinical studies, and education in the disease of the nervous system that causes ataxia and related disorders.
In April 2003, the Paul and Sheila Wellstone Muscular Dystrophy Center (MD Center) was created to facilitate development of clinical, translational, and basic research on muscular dystrophy, to enhance and support clinical care of patients with muscular dystrophy, to improve educational experience for undergraduate, graduate, and professional students interested in the fields of basic and clinical muscle research, and to increase interaction and support from the regional community of patients and families concerned about muscular dystrophy.
MD Center faculty members have 20 NIH grants, 2 NIH training grants and more than $25 million in total direct costs for muscle related research. A prominent couple are:
- Training Program in Muscle Research, Dave Thomas, PhD-Principal Investigator, ongoing NIH NIAMS Sponsorship since May 2001
- Muscular Dystrophy Center Core Laboratories, James Ervasti, PhD-Principal Investigator, ongoing NIH NIAMS Sponsorship since August 2009
MD Center collaborates with other educational institutions, government agencies, private sectors and non-profit organizations to facilitate research, education, and service activities related to muscular dystrophies:
- One of only two NIH P30s for Muscular Dystrophy research (the other at UCLA).
- One of only two NIH P01s for Muscular Dystrophy (the other at University of Washington).
- One of 5 MDA Centers of Excellence for Duchenne Clinical Research (the others at UC-Davis, Washington University St. Louis, Ohio State, and Boston Children’s Hospital).
The largest T32 training program in the country for muscle research, supporting predoctoral, postdoctoral, and both clinical and basic trainees.
Pediatric Blood and Marrow Transplantation Program
In 1968, University of Minnesota physicians completed the world’s first successful bone marrow transplant. Since then, other “world’s firsts” have followed, including:
- The first transplant to treat a patient with lymphoma (1975)
- The first transplant to treat an inherited metabolic disease (1982)
- The first double umbilical cord blood transplant (1999)
- The first umbilical cord blood transplant performed using pre-implantation genetic testing to ensure a perfect tissue match (2000)
- The first reported success in using Natural Killer (NK) cells to successfully treat advanced myelogenous leukemia.
The University of Minnesota Pediatric Blood and Marrow Transplant Program has more experience treating inherited metabolic storage diseases, including Adrenoleukodystrophy (ALD), than any other center in the world. To date, the program has treated hundreds of ALD patients with a blood or marrow transplant.
Clinical and Translational Science Institute (CTSI)
The CTSI at the University of Minnesota is supported through the NIH Clinical and Translational Science Award (CTSA) program.
The institute is one of approximately 60 medical research institutions working together to improve the way clinical and translational research is conducted nationwide, enhancing its efficiency and quality.
The CTSA consortium aims to accelerate the process of translating laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and translational researchers.
Well positioned to support development of K grants.
The CTSI has five main offices, including
- Office of Discovery and Translation: Supports researchers in the early stages of translational research by funding projects, offering consultations, and connecting investigators to translational technologies and experts.
- Clinical Translational Research Services: Provides comprehensive services and support for planning, implementing, conducting, and analyzing clinical studies.
- Populations and Community Engagement: Enables investigators and the community to collaborate on research by matching partners, providing expert consultations, funding projects, and offering resources, tools, and training.
- Biomedical Informatics: Drives the integration of clinical data across the University and Fairview, and gives researchers a one-stop-shop for the data, tools, and information technologies they need to accelerate their research.
- Education, Training, and Research Career Development (CTSI-Ed): Advances the research careers of faculty, staff, and students through education, training, and career development programming.
University of Minnesota Masonic Children’s Hospital
Established in 1905, The University of Minnesota Masonic Children’s Hospital is the only children’s hospital in Minnesota that is part of an academic health center, and is home to one of one of the nation’s top 20 pediatric research programs.
Innovative approaches and affiliation with the University of Minnesota has led to several medical firsts, including
- Minnesota’s first infant heart transplant
- Minnesota’s first pediatric robotically-assisted surgical procedure
- World’s first bone marrow and cord-blood transplant
- Minnesota’s first pediatric cochlear ear implant surgery
- World’s first Berlin Heart device implantation
In 2011 a newly constructed 257-bed facility opened with a 49 bed Level IV NICU and a dedicated pediatric emergency department. The hospital provides patient and family centered care for children in more than 50 pediatric specialties as well as maternal-fetal services.
The facility includes private patient rooms, a 24/7 pediatric-only emergency department with 10 treatment rooms and 2 trauma bays and a children’s dialysis center (the only one in Minnesota).
The latest U.S. News & World Report ranked University of Minnesota Masonic Children’s Hospital among the nation’s best for the seventh consecutive year. The hospital also ranks in the top 50 hospitals in three medical specialties:
- 36th in Nephrology
- 38th in Neonatology
- 36th in Diabetes and Endocrinology (new ranking this year)
The University of Minnesota Masonic Children’s Hospital is further distinguished as being among the world’s largest pediatric kidney transplant programs, a world leader in bone marrow transplant and metabolic disease, and contains the state’s only inpatient behavioral unit.
The University of Minnesota Masonic Children’s Hospital NICU presently has 49 beds, and will expand to 63 in 2015. Two additional NICU’s are located in the North and South Metro suburbs with an average census of 12-18 beds each.
Location – Minneapolis, MN
The University of Minnesota is located in the Twin Cities of Minneapolis and St. Paul, the birth place and headquarters of the American Academy of Neurology (AAN). The quality of life in the Twin cities is very high with multiple regions in the area consistently ranked as some of the best places to live in the US. The Twin Cities is the 16th largest metro area in the US, with a population of approximately 3.3 million people. The Minneapolis-St. Paul area is the 2nd largest economic center in the Midwest, behind Chicago. Minneapolis proper contains the 5th highest concentration of Fortune 500 companies in the country. The presence of the corporate headquarters for companies such as Target, US Bancorp, Xcel Energy and Ameriprise Financial provide a growing economy with great job opportunities for a candidate’s spouse or family.
Notable accolades for the Minneapolis-St. Paul area include:
- Hottest travel destinations in 2013 by Leisure and Travel Magazine (Minneapolis listed first)
- 2013 Top Ten Cities to Live in the U.S.by Top10sTop.com
- Monster.com ranks Minneapolis as 4th best for career advancement
- Minneapolis is 3rd most literate city according to USA Today
- MSP Airport is the 4th best for business travelers according to the Wall Street Journal
- Minneapolis is one of America’s cleanest cities according to a top travel deals publisher
- Minnesota ranks 3rd for quality of life in the U.S. according to Minnesota Public Radio
- Minnesota leads in VC for health care startups according to PR Newswire
- Minneapolis 4th Best in Nation for Health Care according to the Commonwealth Fund
- Twin Cities best placed in U.S. to find employment according to Finance & Commerce
- MSP Airport is #1 Best Airport in America according to Leisure and Travel Magazine